profit from every $100 of sales.
$0$100
Lite Strategy
$0.91-7.94% today
-54.9% in 1 year
1-year low $0.741-year high $2.02
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
You pay $1.52 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Lite Strategy sold, what it kept, and what it did with the cash.
Sales went from $40.7 million in 2022 to $0 in 2025, with -$15.9 million of profit last year.
SalesProfit
Lite Strategy vs. similar companies
Lite Strategy grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lite Strategy | 1.5× · Cheap | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Lite Strategy's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 41 | 49 | 65 | 0 | |
| 41 | – | – | – | |
| -75 | -37 | 25 | -17 | |
| -75 | -36 | 26 | -17 | |
| -54 | -32 | 18 | -16 | |
| -9.99 | -4.78 | 2.67 | -2.39 | |
| 100.0% | – | – | – | |
| -185.5% | -75.3% | 39.0% | – | |
| -133.8% | -65.2% | 27.2% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 178 | 121 | 41 | 18 |
| Cash | 16 | 17 | 4 | 18 |
| Total debt | 10 | 13 | 0 | – |
| Total liabilities | 125 | 96 | 8 | 1 |
| 52 | 25 | 33 | 17 | |
| 6 | 7 | 7 | 7 | |
| -96.1% | -77.8% | 60.9% | -81.4% | |
| -103.9% | -129.3% | 53.8% | -94.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -49 | -52 | -50 | -21 | |
| 0 | 0 | 0 | – | |
| -49 | -53 | -50 | -21 | |
| Dividends paid | – | 0 | 12 | 0 |
| – | – | – | – | |
| 8 | 4 | 2 | -0 |
Valuation
- 1.5×
- –
- –
- 0.1×
- 0.4×
- –
- 0.9×
- -186.3%
- 65.6%
- 0.0%
Profitability
- 0.0%
- 39.0%
- 27.2%
- 0.0%
- -14.7%
- -57.0%
- -68.9%
- -47.9%
- -14.7%
- –
Growth
- +26.7%
- –
- +58.7%
- –
- +4.3%
Financial health
- 0.7×
- 0.00
- 0.0%
- –
- 10.04
- 10.04
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 24%of 952
Top 5%of 883
Top 1%of 576
Top 21%of 870
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.66 | -3.12 | +78.8% |
| Feb 17, 2026 | -0.82 | – | – |
| Nov 14, 2025 | -0.12 | – | – |
| Sep 29, 2025 | -0.40 | – | – |
| May 13, 2025 | -0.39 | – | – |
| Dec 31, 2024 | -0.40 | -2.20 | +81.7% |
| Sep 30, 2024 | -1.20 | -1.70 | +29.3% |
| Jun 30, 2024 | -2.76 | -1.41 | −96.4% |
News
LITE, COHR, AAOI surge as Lumentum CEO says AI parts sold out through early 2029Seeking Alpha · Oct 9, 2026Why Are Nasdaq Futures Surging Premarket? SPCX, ASTS, AAPL, TMUS, VZ, NVDA, MU, LITE Stocks In FocusYahoo Finance · Oct 9, 2026What Does Lumentum Holdings (LITE) Mean For Investors After The LITEON Token Launch?Yahoo Finance · Sep 15, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
5/7Passes 5 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
89Pass
Philip Fisher
64Pass
Peter Lynch
100Pass
Joel Greenblatt
64Pass
Charlie Munger
54No pass
Terry Smith
60Pass
Questions about Lite Strategy
Is Lite Strategy a good stock to buy?
A strong, very profitable business, and the price looks low. 5 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lite Strategy AI analysis
What does Lite Strategy do?
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. It is in Biotechnology.
Does Lite Strategy pay a dividend?
No. Lite Strategy does not pay a dividend at the moment.
Is Lite Strategy stock halal?
No. Lite Strategy does not pass our halal screen: its cash and confirmed interest-bearing investments are 67% of its market value, at or above the 33% limit. How we check
How has Lite Strategy stock done over the past year?
Down 54.9% over the past twelve months, to $0.91. It traded between $0.74 and $2.02 and is 55.1% below its high.
Who are Lite Strategy's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Lite Strategy's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.